EPIC Biotech conference
We are sorry to say that EPIC has been postponed for this year but may resurrected for next year with a content and format to suit biotech companies looking for funding, partners and services.
I'd like to thank all those who have supported and enjoyed the conference over the past 11 years - it has been a pleasure and I hope it has been useful in helping biotechs to develop their business.
What they said about EPIC :
'I sincerely enjoyed the meeting and making some new contacts' Vishal Kapur, Global Licensing, Boehringer Ingelheim
'Thanks for EPIC - it was excellent' - Brian Molloy, CEO Orbsen Therapeutics
'I liked the meeting and it has been productive for me' Wim Jongen, CEO, Glycostem Therapeutics
'We found it valuable for perspective and contacts' John Hart, CEO Endocrine Therapeutics
'EPIC is consistently good value, and very convenient for me to attend'
Dr Susan Davis, Associate Director, Business Development, Cyclacel
‘Thank you and the team for an excellent meeting - the partnering sessions were extremely productive' Elizabeth Rollinson, COO Photobiotics
'I enjoyed myself at the conference and made some good contacts. Overall it was very worthwhile' Henry Rath, Amgen
‘The delegate mix worked well for us as a CRO’
Julie Wright Datatrial
‘Excellent – there were companies and investors that I don’t meet at other networking events’
Patricia Latter, London Bioscience Innovation Centre
The 2015 conference is being held at the King's Fund conference centre at Cavendish Square in central London. The King's Fund is a major player in shaping UK's healthcare system by working with individuals and organisations to shape policy, transform services and bring about behaviour change.
Partnering is an essential component of the conference - especially for those seeking licensing deals. The on-line partnering enables delegates to arrange 1:1 meetings on the day with the presenting companies or fellow delegates. Partnering will be open from 5 weeks before the conference until the day before the conference starts.
Many of the presenting biotechnology companies are looking for funding through venture capital routes and have the opportunity to pitch to investors. Investment via development deals with big pharma is also an important route for company development and EPIC provides the perfect platform to start negotiations.
To compliment the structured partnering there will be informal networking throughout the day with a mix of companies, investors and scientists plus a networking drinks reception to end the day. Limited exhibition stands are available for company promotion and networking.
If you are interested in taking part please contact:
Presenting and sponsoring contact the EPIC Director, Simon Tarpey at firstname.lastname@example.org or on +353 863060225